Primary pleural epithelioid haemangioendothelioma with metastases to the skin. A case report and literature review

M Al-Shraim, B Mahboub, P C Neligan, D Chamberlain, D Ghazarian

Epithelioid haemangioendothelioma (EHE) is a rare vascular tumour of intermediate behaviour. It can arise from various sites including the liver, spleen, pleura, or lung. Cutaneous EHE can be primary or secondary. This report describes the case of a 51 year old man who presented with a history of dry cough, shortness of breath, and pleural effusion, and who developed two cutaneous nodules in the anterior abdominal wall a few weeks later. He had a previous history of asbestos exposure. Computed tomography scan showed a left sided pleural effusion and nodular pleural mass. Histology of both the pleural and cutaneous lesions was compatible with EHE. Electron microscopic examination demonstrated the presence of Weibel-Palade bodies. The patient underwent elliptical excision of the metastatic cutaneous nodules after decortication of the primary pleural tumour and adjuvant treatment. A few reports have described metastasis of intrathoracic EHE to the skin. Despite treatment with interferon, the patient developed more cutaneous lesions two years after the initial diagnosis. Even though the tumour has the classic light histological and ultrastructural features of EHE, it behaved in an aggressive manner.

A 51 year old man presented with a history of dry cough, which was treated initially with bronchodilator, but with no improvement; one week later he developed shortness of breath on exertion. Chest x ray showed a pronounced left sided pleural effusion. The bronchoscopic examination was unremarkable. He underwent pleuroscopy with multiple pleural biopsies, and the results were interpreted at his regional hospital as malignant mesothelioma, undifferentiated, small cell type. His past medical history revealed exposure to asbestos for two to three months about 25 years previously. The patient was referred to Princess Margaret Hospital, Toronto, Canada, for further management. The patient received one cycle of vinorelbine and cisplatin based on the presumed diagnosis of mesothelioma. The patient underwent elliptical excision of the metastatic subcutaneous nodules. These skin lesions had an identical histology to the primary pleural tumour (fig 2A). The tumour showed abundant eosinophilic stroma with focal areas of necrosis. These tumour cells showed moderate and diffuse (approximately 95%) immunoreactivity for CD31 (fig 3A) and factor VIII, strong and diffuse (approximately 95%) immunoreactivity for CD34 (fig 3B), strong and diffuse (approximately 80%) immunoreactivity for monoclonal carcinoembryonic antigen (CEA; fig 3C) and vimentin (fig 3D), and weak and focal immunoreactivity (approximate 5%) for cytokeratin 7. No immunoreactivity for thyroid transcription factor 1 or BerEP4 was seen. Electron microscopic examination revealed Weibel-Palade bodies (fig 4). The patient was started on three subcutaneous injections of 7000 000 units of interferon x each week. A few weeks later he developed small, multiple, subcutaneous nodules on his anterior abdominal wall. They were firm, mobile, and mildly tender to pressure. The patient underwent elliptical excision of these subcutaneous nodules. These skin lesions had an identical histology to the primary pleural tumour (fig 2B) and showed a similar immunoreactive pattern for CD31, CD34, vimentin, and monoclonal CEA. Serial thoracic CT scans showed no interval change in the size of the residual tumour over a follow up period of two years. Abdominal CT scans showed moderate pelvic ascites, which

Abbreviations: CEA, carcinoembryonic antigen; CT, computed tomography; EHE, epithelioid haemangioendothelioma

Figure 1 Computed tomography scan showing pleural thickening, a nodular mass in the inferior left pleural surface, and a pleural effusion with multiple gas loculations.
were unchanged from the previous scans. The patient continued on interferon treatment. More recently he has developed more cutaneous nodules on his trunk.

**DISCUSSION**

EHE is a rare vascular tumour of intermediate behaviour, which was first described by Weiss and Enzinger in 1982. It can originate from the soft tissue, lung, pleura, liver, bone, breast, brain, or meninges. It is extremely rare for EHE to arise from the skin as a primary tumour. We describe the case of a 51 year old man who developed multiple metastatic cutaneous lesions of EHE from a pleural primary location. He had a history of exposure to asbestos. A histological and immunopathological examination of both the lesions was compatible with EHE. The tumour cells stained negatively for mesothelium associated markers. The diagnosis of EHE was confirmed by the demonstration of Weibel-Palade bodies on electron microscopy. The association between exposure to asbestos and the development of several pleural lesions including malignant mesothelioma, hyaline plaques, and diffuse pleural fibrosis has been well established. However, the patient’s exposure to asbestos was short and he had no radiological features, such as pleural plaques; in addition, the association between asbestos and pleural epithelioid haemangioendothelioma has been postulated only in one series of three patients. EHE can mimic malignant mesothelioma clinically, radiologically, and histomorphologically, so that EHE should be suspected in any lesion of pleural malignant mesothelioma, because the management and the prognosis of these two diseases are different. On light microscopic examination, EHE can mimic mesothelioma; however, immunohistochemical staining for vascular markers such as CD31, CD34, and factor VIII can help to distinguish it from mesothelioma. A few reports described the metastasis of primary intrathoracic EHE to the skin. The cutaneous lesions seen in our patient showed a similar histology; this was interpreted as a metastatic lesion from the primary pleural lesion.

The expression of monoclonal CEA has been investigated by immunohistochemical studies as a prognostic marker of the biological aggressiveness of many human tumours, including thymic carcinomas, colorectal carcinomas, synovial sarcomas, and others. The expression of monoclonal CEA in our case is an unusual and interesting finding, which might be related to the aggressive course of this vascular tumour. However, its prognostic value for EHE remains a subject for further investigations. According to the literature, EHE is negative for monoclonal CEA. This is based on only a few rare reported cases. We recently noticed that some
Epithelioid haemangioendotheliomas stain positively for monoclonal CEA, although the importance of this observation is uncertain. Cytokeratin expression has also been described in EHE.22 23

"Epithelioid haemangioendothelioma should be suspected in any lesion of pleural malignant mesothelioma, because the management and the prognosis of these two diseases are different"

The surgical treatment of EHE is complete excision or debulking of the tumour. Different adjuvant treatments have been proposed including interferon, interleukin 2, and retinooids.24 Regardless of the presence of the morphological features of EHE, most cases of pleural EHE behave much more aggressively than EHE arising from other sites.25

ACKNOWLEDGEMENTS

We wish to thank our senior electron microscopy technologist S Ramjoh for his contribution.

REFERENCES


Figure 4 Electron micrograph showing Weibel-Palade bodies.
Primary pleural epithelioid haemangioendothelioma with metastases to the skin. A case report and literature review

M Al-Shraim, B Mahboub, P C Neligan, D Chamberlain and D Ghazarian

doi: 10.1136/jcp.2004.018937

Updated information and services can be found at:
http://jcp.bmj.com/content/58/1/107

These include:

**References**

This article cites 24 articles, 3 of which you can access for free at:
http://jcp.bmj.com/content/58/1/107#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Immunology (including allergy) (1664)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/